What question did this study set out to answer?

The aim is to investigate how the in vivo evolution of antibody CR3022 enhances its ability to neutralize various SARS-CoV-2 variants and understand its role in broader immunity against sarbecoviruses.

March 24, 2026Open Access

In vivo evolution of antibody CR3022 expands cross-neutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity

Key Result

In vivo evolution of the CR3022 antibody expands its cross-neutralization of SARS-CoV-2 variants and provides insights into pan-sarbecovirus immunity.

Key Points

The aim is to investigate how the in vivo evolution of antibody CR3022 enhances its ability to neutralize various SARS-CoV-2 variants and understand its role in broader immunity against sarbecoviruses.
In vivo evolution of antibody CR3022
Assessment of cross-neutralization efficacy against SARS-CoV-2 variants
Analysis of immune response patterns
Antibody CR3022 shows increased potency against multiple SARS-CoV-2 variants after evolution.
Induces a broader immune response that may inform strategies for pan-sarbecovirus immunity.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

In vivo evolution of antibody CR3022 expands crossneutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Fu et al. (Sat,) reported a other. In vivo evolution of the CR3022 antibody expands its cross-neutralization of SARS-CoV-2 variants and provides insights into pan-sarbecovirus immunity.

synapsesocial.com/papers/69c2294caeb5a845df0d38c2 https://doi.org/https://doi.org/10.1016/j.celrep.2026.117137